ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

Eliminating Hepatitis C Virus

Completed

Conditions: Hepatitis C
Type2 Diabetes
HIV

First Posted Date: 2018-01-17

Last Posted Date: 2021-03-24

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 52

Registration Number: NCT03401697

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Computerized Cognitive Intervention in the Oldest-Old

Not Applicable

Completed

Conditions: Dementia
Cognition

Interventions: Behavioral: Control-games
Behavioral: CogniFit™

First Posted Date: 2018-01-12

Last Posted Date: 2018-01-12

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 69

Registration Number: NCT03397498

Locations: 🇺🇸
Jewish Home Lifecare, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinia, New York, New York, United States

Reducing the Duration of Untreated Psychosis in the United States

Completed

Conditions: First Episode Psychosis (FEP)
At Risk Mental State (ARMS)

First Posted Date: 2017-12-12

Last Posted Date: 2021-12-14

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 94

Registration Number: NCT03369730

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Trustees of Boston University, Boston, Massachusetts, United States
🇺🇸
Research Foundation/City University of New York (CUNY) on behalf of CUNY Graduate School, New York, New York, United States

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2017-12-02

Last Posted Date: 2022-09-13

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT03359356

Locations: 🇺🇸
The Rockefeller University Laboratory for Investigative Dermatology, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients

Phase 2

Completed

Conditions: Induction of Labor Affected Fetus / Newborn

Interventions: Drug: Placebo
Drug: Propranolol

First Posted Date: 2017-11-21

Last Posted Date: 2020-01-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 240

Registration Number: NCT03348683

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps

Phase 2

Completed

Conditions: Head and Neck Cancer
Free Tissue Transfer

Interventions: Drug: Ropivicaine
Drug: Local Saline Infusion

First Posted Date: 2017-11-21

Last Posted Date: 2020-11-17

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 24

Registration Number: NCT03349034

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Anxiety About Casual Exposure to Food Allergens

Not Applicable

Completed

Conditions: Food Allergy

Interventions: Behavioral: Education
Behavioral: Behavioral intervention group

First Posted Date: 2017-11-21

Last Posted Date: 2019-02-21

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT03349047

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma
GBM

Interventions: Drug: Avelumab
Combination Product: MRI-guided LITT therapy

First Posted Date: 2017-11-14

Last Posted Date: 2022-01-04

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 13

Registration Number: NCT03341806

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Phase 2

Terminated

Conditions: Locally Advanced Breast Cancer

Interventions: Drug: Docetaxel
Drug: Pertuzumab
Drug: Carboplatin
Drug: Trastuzumab
Drug: Doxorubicin
Drug: Pegfilgrastim
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2017-11-06

Last Posted Date: 2023-08-22

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 7

Registration Number: NCT03329378

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸
Mount Sinai West, New York, New York, United States

Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?

Phase 4

Completed

Conditions: Knee Rheumatism
Knee Osteoarthritis

Interventions: Drug: Obturator nerve regional block
Drug: Saline
Drug: Adductor canal regional block

First Posted Date: 2017-10-31

Last Posted Date: 2020-09-30

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT03326999

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy